Study Comparing Two Treatment Approaches for Newly Diagnosed Multiple Myeloma: DVRd with Ciltacabtagene Autoleucel vs. DVRd with Stem Cell Transplant

Sponsor: Stichting European Myeloma Network

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05257083

Provider View

This clinical trial is comparing two treatment methods for patients with newly diagnosed multiple myeloma. One group will receive a combination of drugs followed by a new type of cell therapy, while the other group will receive the same drugs followed by a stem cell transplant.

Patient Parameters

Program Overview

The study aims to find out which treatment is more effective for newly diagnosed multiple myeloma: a combination of drugs (Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone) followed by a new cell therapy called Ciltacabtagene Autoleucel, or the same drug combination followed by a traditional stem cell transplant. The study will involve about 750 participants, who will be randomly assigned to one of the two treatment groups.

Description

Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow, leading to the production of abnormal proteins. This study is testing a new treatment approach using a cell therapy called Ciltacabtagene Autoleucel, which is a type of CAR-T therapy targeting a specific protein on cancer cells. The goal is to see if this new therapy can improve outcomes for patients compared to the standard treatment of a stem cell transplant. Participants will be randomly assigned to receive either the new cell therapy or the stem cell transplant after initial treatment with a combination of drugs. The study will measure how long patients remain free from disease progression and other health outcomes.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of newly diagnosed multiple myeloma (NDMM) and are eligible for high-dose therapy and stem cell transplant as part of their initial treatment plan.
  • Have measurable disease based on specific laboratory tests, such as:
    • Serum M-protein level of at least 1.0 g/dL or urine M-protein level of at least 200 mg/24 hours.
    • For light chain multiple myeloma without measurable disease in serum or urine: serum free light chain (FLC) level of at least 10 mg/dL and an abnormal serum kappa lambda FLC ratio.
  • Have an ECOG performance status of 0 or 1, indicating full activity or some restriction in strenuous activities.
  • Have clinical laboratory values within specified ranges.

Exclusion Criteria

  • Have received any prior CAR-T therapy targeting any protein.
  • Have received any prior therapy targeting BCMA.
  • Have received any prior treatment for multiple myeloma or smoldering myeloma, except for a short course of corticosteroids.
  • Have taken a strong CYP3A4 inducer within five half-lives before randomization.
  • Have received or plan to receive any live, attenuated vaccine (except COVID-19 vaccines) within four weeks before randomization.
  • Have known active or prior central nervous system involvement or signs of meningeal involvement of multiple myeloma.
  • Have had a stroke or seizure within six months of signing the informed consent form.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.